Flyout Menu
Search

Pharma

Value

To be able to find the right path for the introduction of a medicine in Italy, it is necessary to explore and translate the map of the regulatory environment, identifying and analysing the expectations and reports of decision-makers.

We assist those who turn to us in understanding and obtaining a fair price and reimbursement for a medicine. Finding a common ground, by appropriately mediating between Company profit, patient needs and the limited resources of the National Health Service, is a victory for all interest groups involved.
Through the years, we have learnt that the reality of things is more complex than whatever had been planned.
Even when everything is well-prepared and strategies corresponding to the value of the medicine, in accordance with the regulatory objectives of the agencies, and accommodating to drug governance guidelines, are proposed, the pathway to the authorisation of a medicine may well progress differently than expected. Not to mention any external variables that could slow down, if not hinder, the access of a medicine to the market.
Integrated skills are needed to help with navigation
Though quite detailed, the map we have provided cannot define the complexity of the terrain. Our experience comes to the aid when it is not clear.
About us
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
Notes

Summary of the Consolidated Text on Rare Diseases

4 November 2021
On 26 May 2021, the Chamber of Deputies, after more than two years of work in the Social Affairs Committee, approved the bill ...
Team Pharma Value

Pharma Value Code of Ethics

18 October 2021
Being aware of the right value of a drug is a conviction that has inspired Pharma Value's actions, ever since the choice of the ...
Team Pharma Value

Our meeting staff in Florence

20 September 2021
Today from our LinkedIn page we are not telling you what is happening in the pharma world but what is happening at home ...
SPECIAL DRUG EVALUATION COMMISSIONS. AIFA commissions from 2004 to 2021 Scenario analysis

SPECIAL DRUG EVALUATION COMMISSIONS. AIFA commissions from 2004 to 2021

3 September 2021
NOMOS Centro Studi Parlamentari e Pharma Value hanno realizzato uno speciale sulle commissioni per la valutazione dei farmaci, precisamente la Commissione Tecnico ...
Team Pharma Value

Thoughts, the Newsletter

16 July 2021
Pensierini sarà la Newsletter di Valeria Viola, una mail che non racconterà specificamente le attività di Pharma Value, così come non sarà ...
Special - The rules for CTS and CPR renewal AIFA Notes

The renewal of the AIFA Commissions is imminent. What are the rules?

28 June 2021
A settembre scadranno le Commissioni AIFA (CTS e CPR). NOMOS centro studi parlamentari e Pharma Value fanno il punto sulle regole per ...
Rare Diseases Table Notes

Who are the members of the technical table for rare diseases of the Ministry of Health

25 June 2021
Il 21 giugno 2021 è stato istituito il Tavolo tecnico in tema di malattie rare. Il Tavolo riunisce esperti clinici e accademici, ...
Team Pharma Value

Privilege is invisible to the eyes.

7 June 2021
Abbiamo chiesto alla Fondazione Giacomo Brodolini di aiutarci a ragionare sul privilegio, in questo mese del Pride dove i social si colorano ...
ERN and rare diseases - report Notes

ERN and rare diseases: the report of the Incisive Health Morning Club co-organised by Nomos, in collaboration with Pharma Value

3 June 2021
Il 20 maggio si è tenuto l’Incisive Health Morning Club co-organizzato da Nomos Centro Studi Parlamentari e Pharma Value in collaborazione con ...
Scenario analysis

Modification of national requirements in the blue box for medicines

9 April 2021
AIFA ha pubblicato una comunicazione sull’aggiornamento circa i requisiti nazionali da inserire in Blue Box. C’è un impatto importante sulle attività regolatorie ...
en_GB
it_IT en_GB